Aerie Pharmaceuticals Inc. will launch its first of two glaucoma drugs in the middle of the second quarter of 2018 as planned even though the US FDA approved Rhopressa two months earlier than expected. Even then it will take another seven or eight months for half of the drug's patients to gain access.
Irvine, Calif.-based Aerie said on Dec. 18 that Rhopressa (netarsudil ophthalmic solution 0.02%) was approved for the lowering of elevated...






